BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993;85:1839-1844. [PMID: 8230264 DOI: 10.1093/jnci/85.22.1839] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Persiani R, D’Ugo D, Rausei S, Sermoneta D, Barone C, Pozzo C, Ricci R, La Torre G, Picciocchi A. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol. 2005;89:227-36; discussion 237-8. [PMID: 15726615 DOI: 10.1002/jso.20207] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
2 Dank M. [Recent advances in the treatment of gastric cancer]. Magy Onkol 2010;54:337-41. [PMID: 21163764 DOI: 10.1556/MOnkol.54.2010.4.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep 2004;6:192-8. [PMID: 15066230 DOI: 10.1007/s11912-004-0049-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003;21:223-227. [PMID: 14648779 DOI: 10.1002/ssu.10040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
5 De Vivo R, Pignata S, Palaia R, Parisi V, Daniele B. The role of chemotherapy in the management of gastric cancer. J Clin Gastroenterol 2000;30:364-71. [PMID: 10875463 DOI: 10.1097/00004836-200006000-00004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
6 Lawson JD, Sicklick JK, Fanta PT. Gastric cancer. Curr Probl Cancer. 2011;35:97-127. [PMID: 21635986 DOI: 10.1016/j.currproblcancer.2011.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
7 Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303-308. [PMID: 10077040 DOI: 10.1097/00000658-199903000-00001] [Cited by in Crossref: 179] [Cited by in F6Publishing: 160] [Article Influence: 7.8] [Reference Citation Analysis]
8 Jonsson L, Hedner C, Gaber A, Korkocic D, Nodin B, Uhlén M, Eberhard J, Jirström K. High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomark Res 2014;2:11. [PMID: 24963396 DOI: 10.1186/2050-7771-2-11] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
9 In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer 2018;21:1-9. [PMID: 28948368 DOI: 10.1007/s10120-017-0765-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
10 Biondi A, Lirosi MC, D’Ugo D, Fico V, Ricci R, Santullo F, Rizzuto A, Cananzi FC, Persiani R. Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World J Gastrointest Oncol 2015; 7(12): 389-400 [PMID: 26690252 DOI: 10.4251/wjgo.v7.i12.389] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
11 Stein HJ, Sendler A, Fink U, Siewert JR. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am. 2000;80:659-682; discussions 683-686. [PMID: 10836011 DOI: 10.1016/s0039-6109(05)70205-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
12 Gunderson LL, Tepper JE, Calvo FA, Callister MD. Gastric/GE Junction Cancer. Clinical Radiation Oncology. Elsevier; 2012. pp. 903-33. [DOI: 10.1016/b978-1-4377-1637-5.00045-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Ajani J. Therapy of carcinoma of the oesophagus: Either attempt it not or succeed. European Journal of Cancer 1995;31:790-3. [DOI: 10.1016/0959-8049(94)e0124-m] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol. 2003;4:498-505. [PMID: 12901965 DOI: 10.1016/s1470-2045(03)01170-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
15 Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006;107:1475-1482. [PMID: 16944539 DOI: 10.1002/cncr.22180] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
16 Weese JL, Harbison SP, Stiller GD, Henry DH, Fisher SA. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): Improved treatment for gastric adenocarcinoma. Surgery 2000;128:564-71. [DOI: 10.1067/msy.2000.108420] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
17 Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2005;54:209-241. [PMID: 15890270 DOI: 10.1016/j.critrevonc.2005.01.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
18 Siewert J, Fink U, Sendler A, Becker K, Böttcher K, Feldmann H, Höfler H, Mueller J, Molls M, Nekarda H, Roder J, Stein H. Gastric cancer. Current Problems in Surgery 1997;34:835-939. [DOI: 10.1016/s0011-3840(97)80006-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Roth AD. Curative treatment of gastric cancer: towards a multidisciplinary approach? Crit Rev Oncol Hematol. 2003;46:59-100. [PMID: 12672518 DOI: 10.1016/S1040-8428(02)00160-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
20 Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers CB, Verspaget HW. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 1996;77:1035-43. [PMID: 8635120 DOI: 10.1002/(sici)1097-0142(19960315)77:6<1035::aid-cncr5>3.0.co;2-g] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
21 House MG, Brennan MF. Neoadjuvant therapy for gastric cancer. Adv Surg. 2008;42:151-168. [PMID: 18953815 DOI: 10.1016/j.yasu.2008.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
22 Roth AD, Allal AS, Bründler MA, de Peyer R, Mermillod B, Morel P, Huber O. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study. Ann Oncol. 2003;14:110-115. [PMID: 12488302 DOI: 10.1093/annonc/mdg023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
23 Shchepotin IB, Chorny V, Hanfelt J, Evans SR. Palliative superselective intra-arterial chemotherapy for advanced nonresectable gastric cancer. J Gastrointest Surg. 1999;3:426-431. [PMID: 10482696 DOI: 10.1016/s1091-255x(99)80060-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Persiani R, Rausei S, Biondi A, D'Ugo D. Perioperative chemotherapy for gastric cancer: how should we measure the efficacy? Ann Surg Oncol 2009;16:1077-9. [PMID: 19169756 DOI: 10.1245/s10434-008-0310-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001;92:279-86. [PMID: 11466680 DOI: 10.1002/1097-0142(20010715)92:2<279::aid-cncr1320>3.0.co;2-2] [Cited by in Crossref: 91] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
26 Chen CN, Cheng YM, Lin MT, Hsieh FJ, Lee PH, Chang KJ. Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer. Ann Surg. 2002;235:512-518. [PMID: 11923607 DOI: 10.1097/00000658-200204000-00009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
27 D'Ugo D, Rausei S, Biondi A, Persiani R. Preoperative treatment and surgery in gastric cancer: friends or foes? Lancet Oncol. 2009;10:191-195. [PMID: 19185837 DOI: 10.1016/s1470-2045(09)70021-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
28 Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol 2000;16:516-21. [PMID: 17031130 DOI: 10.1097/00001574-200011000-00009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
29 Içli F, Karaoguz H, Akbulut H, Dinçol D, Demirkazik A, Çay F. Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer. J Surg Oncol 1997;64:318-23. [DOI: 10.1002/(sici)1096-9098(199704)64:4<318::aid-jso13>3.0.co;2-z] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
30 Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Jensen K; GE Adenocarcinoma Meta-analysis Group. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;5:CD008107. [PMID: 23728671 DOI: 10.1002/14651858.cd008107.pub2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
31 Yao J, Ajani J. Therapy of localized gastric cancer: preoperative and postoperative approaches. Annals of Oncology 2002;13:7-12. [DOI: 10.1093/annonc/mdf632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
32 Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, Wu Q, Zong XL, Ren H, Tang L, Zhang XP, Li JY, Hu Y, Shen L, Ji JF. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105:793-799. [PMID: 22189752 DOI: 10.1002/jso.23009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
33 Rajdev L. Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol. 2010;11:14-23. [PMID: 20358316 DOI: 10.1007/s11864-010-0117-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
34 Gallardo-rinc�n D, O�ate-oca�a LF, Calderillo-ruiz G. Neoadjuvant Chemotherapy With P-ELF (Cisplatin, Etoposide, Leucovorin, 5-Fluorouracil) Followed by Radical Resection in Patients With Initially Unresectable Gastric Adenocarcinoma: A Phase II Study. Ann Surg Oncol 2000;7:45-50. [DOI: 10.1007/s10434-000-0045-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
35 Marcus SG, Cohen D, Lin K, Wong K, Thompson S, Rothberger A, Potmesil M, Hiotis S, Newman E. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg. 2003;7:1015-1022; discussion 1023. [PMID: 14675711 DOI: 10.1016/j.gassur.2003.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
36 Papenfuss WA, Kukar M, Oxenberg J, Attwood K, Nurkin S, Malhotra U, Wilkinson NW. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol. 2014;21:3008-3014. [PMID: 24700300 DOI: 10.1245/s10434-014-3664-z] [Cited by in Crossref: 121] [Cited by in F6Publishing: 114] [Article Influence: 15.1] [Reference Citation Analysis]
37 Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597-608. [PMID: 12699095 DOI: 10.1080/11024150201680005] [Cited by in Crossref: 152] [Cited by in F6Publishing: 138] [Article Influence: 8.0] [Reference Citation Analysis]
38 Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Critical Reviews in Oncology/Hematology 2009;71:127-64. [DOI: 10.1016/j.critrevonc.2009.01.004] [Cited by in Crossref: 266] [Cited by in F6Publishing: 262] [Article Influence: 20.5] [Reference Citation Analysis]
39 Li Y, Chen J, He Q, Ji X, Wang X, Fan C, Li G. Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis. Oncotarget 2017;8:86886-96. [PMID: 29156843 DOI: 10.18632/oncotarget.19004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
40 Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995;19:216-220. [PMID: 7754626 DOI: 10.1007/bf00308629] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
41 Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774-2780. [PMID: 15254045 DOI: 10.1200/jco.2004.01.015] [Cited by in Crossref: 229] [Cited by in F6Publishing: 87] [Article Influence: 12.7] [Reference Citation Analysis]
42 Foukakis T, Lundell L, Gubanski M, Lind PA. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 2007;46:277-85. [PMID: 17450463 DOI: 10.1080/02841860701218634] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
43 Liu J, Qu XJ, Xu L, Zang Y, Qu JL, Hou KZ, Liu YP. Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells. Dig Dis Sci. 2010;55:3361-3368. [PMID: 20393880 DOI: 10.1007/s10620-010-1191-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
44 Das P, Ajani JA. Gastric and gastro-oesophageal cancer therapy. Expert Opin Pharmacother. 2005;6:2805-2812. [PMID: 16318431 DOI: 10.1517/14656566.6.16.2805] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
45 Li Y, Wei Y, He Q, Wang X, Fan C, Li G. Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Sci Rep 2018;8:6223. [PMID: 29670115 DOI: 10.1038/s41598-018-24259-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Samalin E, Ychou M. Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts? Curr Opin Oncol 2007;19:384-9. [PMID: 17545805 DOI: 10.1097/CCO.0b013e3281a73674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
47 Kobayashi O, Tsuburaya A, Yoshikawa T, Osaragi T, Murakami H, Yoshida T, Sairenji M. The efficacy of gastrectomy for large gastric cancer. Int J Clin Oncol 2006;11:44-50. [PMID: 16508728 DOI: 10.1007/s10147-005-0535-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
48 Elimova E, Ajani JA. Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options? J Clin Oncol 2015;33:3085-91. [PMID: 26324361 DOI: 10.1200/JCO.2014.60.1765] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
49 Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med 2020;6:147-57. [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Hartgrink HH, Bonenkamp HJ, van de Velde CJ. Influence of Surgery on Outcomes in Gastric Cancer. Surgical Oncology Clinics of North America 2000;9:97-117. [DOI: 10.1016/s1055-3207(18)30171-6] [Cited by in Crossref: 24] [Article Influence: 1.1] [Reference Citation Analysis]
51 Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 1995;75:451-6. [DOI: 10.1002/1097-0142(19950115)75:2<451::aid-cncr2820750207>3.0.co;2-u] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
52 Gonzalez RJ, Mansfield PF. Adjuvant and neoadjuvant therapy for gastric cancer. Surg Clin North Am. 2005;85:1033-1051, viii. [PMID: 16139035 DOI: 10.1016/j.suc.2005.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
53 Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced Staging and All Chemotherapy Preoperatively in Patients with Potentially Resectable Gastric Carcinoma. JCO 1999;17:2403-2403. [DOI: 10.1200/jco.1999.17.8.2403] [Cited by in Crossref: 71] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
54 Shaveta, Singh P. Structural optimization of indole based compounds for highly promising anti-cancer activities: Structure activity relationship studies and identification of lead molecules. European Journal of Medicinal Chemistry 2014;74:440-50. [DOI: 10.1016/j.ejmech.2013.12.047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
55 Xu W, Beeharry MK, Liu W, Yan M, Zhu Z. Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine. Biomed Res Int 2016;2016:3923585. [PMID: 28105420 DOI: 10.1155/2016/3923585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
56 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292 [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
57 Mezhir JJ, Tang LH, Coit DG. Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol. 2010;101:305-314. [PMID: 20187070 DOI: 10.1002/jso.21483] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
58 Biondi A, Persiani R, Cananzi F, Zoccali M, Vigorita V, Tufo A, D’Ugo D. R0 resection in the treatment of gastric cancer: Room for improvement. World J Gastroenterol 2010; 16(27): 3358-3370 [PMID: 20632437 DOI: 10.3748/wjg.v16.i27.3358] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
59 Rausei S, Dionigi G, Rovera F, Boni L, Valerii C, Giavarini L, Frattini F, Dionigi R. A decade in gastric cancer curative surgery: Evidence of progress (1999-2009). World J Gastrointest Surg 2012; 4(3): 45-54 [PMID: 22530078 DOI: 10.4240/wjgs.v4.i3.45] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
60 Tentes AK, Markakidis SK, Karanikiotis C, Fiska A, Tentes IK, Manolopoulos VG, Dimitriou T. Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. Langenbecks Arch Surg 2006;391:124-9. [DOI: 10.1007/s00423-006-0022-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
61 Starling N, Cunningham D. The role of systemic therapy for localised gastric cancer. Annals of Oncology 2006;17:x114-21. [DOI: 10.1093/annonc/mdl248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 Costa F, Schwartz G, Kelsen D. Adjuvant chemotherapy in gastric adenocarcinomas. Cancer Treat Res 1998;98:41-63. [PMID: 10326664 DOI: 10.1007/978-1-4615-4977-2_2] [Reference Citation Analysis]
63 Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-1530. [PMID: 14508841 DOI: 10.1002/cncr.11660] [Cited by in Crossref: 401] [Cited by in F6Publishing: 377] [Article Influence: 21.1] [Reference Citation Analysis]
64 Morita S, Fukagawa T, Fujiwara H, Katai H. Questionnaire survey regarding the current status of super-extended lymph node dissection in Japan. World J Gastrointest Oncol 2016; 8(9): 707-714 [PMID: 27672429 DOI: 10.4251/wjgo.v8.i9.707] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
65 Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep. 2002;4:222-228. [PMID: 11937012 DOI: 10.1007/s11912-002-0019-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
66 Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006; 12(2): 204-213 [PMID: 16482619 DOI: 10.3748/wjg.v12.i2.204] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 62] [Article Influence: 3.9] [Reference Citation Analysis]
67 Fink U, Stein HJ, Schuhmacher C, Wilke HJ. Neoadjuvant chemotherapy for gastric cancer: update. World J Surg. 1995;19:509-516. [PMID: 7676692 DOI: 10.1007/bf00294711] [Cited by in Crossref: 38] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
68 Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 2007;110:989-95. [PMID: 17636525 DOI: 10.1002/cncr.22870] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
69 Zhao WH, Wang SF, Ding W, Sheng JM, Ma ZM, Teng LS, Wang M, Wu FS, Luo B. Apoptosis induced by preoperative oral 5’-DFUR administration in gastric adenocarcinoma and its mechanism of action. World J Gastroenterol 2006; 12(9): 1356-1361 [PMID: 16552801 DOI: 10.3748/wjg.v12.i9.1356] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
70 Giuliani A, Miccini M, Basso L. Extent of lymphadenectomy and perioperative therapies: Two open issues in gastric cancer. World J Gastroenterol 2014; 20(14): 3889-3904 [PMID: 24744579 DOI: 10.3748/wjg.v20.i14.3889] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
71 Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, Helmberger A, Böttcher K, Siewert JR. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995;82:1248-52. [PMID: 7552009 DOI: 10.1002/bjs.1800820930] [Cited by in Crossref: 78] [Cited by in F6Publishing: 61] [Article Influence: 2.9] [Reference Citation Analysis]
72 Wang K, Ren Y, Ma Z, Li F, Cheng X, Xiao J, Zhang S, Yu Z, Yang H, Zhou H, Li Y, Liu H, Jiao ZY. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis. Cancer Manag Res 2019;11:3009-20. [PMID: 31114348 DOI: 10.2147/CMAR.S200883] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
73 Chang AY, Foo KF, Koo WH, Ong S, So J, Tan D, Lim KH. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol 2016;3:e000095. [PMID: 27648294 DOI: 10.1136/bmjgast-2016-000095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
74 Gunderson LL, Donohue JH, Alberts SR. Cancer of the Stomach. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1431-64. [DOI: 10.1016/b978-0-443-06694-8.50083-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
75 Ajani J, Roth J, Putnam J, Walsh G, Lynch P, Roubein L, Ryan M, Natrajan G, Gould P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. European Journal of Cancer 1995;31:665-70. [DOI: 10.1016/0959-8049(94)00318-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
76 Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23:6220-6232. [PMID: 16135489 DOI: 10.1200/jco.2005.11.593] [Cited by in Crossref: 112] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
77 Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Jensen K; GE Adenocarcinoma Meta-analysis Group. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;5:CD008107. [PMID: 23728671 DOI: 10.1002/14651858.cd008107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]